Stay updated on Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.

Latest updates to the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page
- Check4 days agoChange DetectedThe page revision was updated to v3.6.6, indicating a small platform-level update. It does not change trial details, eligibility criteria, outcomes, or other substantive content on the study page.SummaryDifference0.1%

- Check11 days agoChange DetectedThe study's external identifiers now include an NIH funding reference for 2017, adding funding attribution to the record.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now displays a new revision version (v3.6.5) replacing the previous one, indicating a release update. This update pertains to the site's software layer rather than the clinical trial data or public text.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page now shows a new revision tag 'Revision: v3.6.4' replacing the previous 'Revision: v3.6.3'. This indicates a minor update to the study record page's metadata rather than a change to the study content.SummaryDifference0.1%

- Check61 days agoChange DetectedFooter revision updated from v3.6.2 to v3.6.3, indicating a new page build. The change does not modify study information or user-facing content.SummaryDifference0.1%

- Check68 days agoChange DetectedFooter shows Revision: v3.6.2 instead of v3.6.0, indicating a minor update to the site interface.SummaryDifference0.1%

Stay in the know with updates to Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.